The dVAM Product Advisory Committee has been established to provide an independent oversight over the dVAM funds, the Investment Manager and the Sub-Investment Managers who manage the various dVAM funds.  In addition, the Committee provides input on all aspects of the strategy, research, analysis, design and development of new funds within the range. The dVAM Product Advisory Committee’s role is to bridge the gap between the Investment Manager and our investors. 

 

THE ROLE OF THE COMMITTEE

The Committee has Terms of Reference which have been approved by the Boards of the Company and the ultimate holding company, deVere Group Ltd, under which it will monitor, and if appropriate make recommendations about all aspects of the dVAM funds.  The Committee will report directly to the Boards of the Company and of deVere and it will meet at least quarterly, with the permanent members being joined by regular attendees, including the Investment Manager and Sub-Investment Managers of the various funds. 

 

WHAT DOES THE PRODUCT ADVISORY COMMITTEE DO:

•    Reviews adherence to fund objectives. 
•    Reviews investment performance and outcomes.
•    Reviews operational performance and management of the dVAM funds.
•    Commissions ongoing market research, product benchmarking, peer group reviews and customer surveys, to enable the provision of strategic guidance to the Investment Manager on the proposition, structure, pricing and investment objectives of the Funds, ensuring that the Funds remain suitable for the target investors at all times.
•    Receive and consider proposals for new funds or changes to existing funds from the Investment Manager or the wider deVere Group.
•    Review and consider developments in the industry (i.e. regulations, tax, competition, etc.) that create new opportunities or challenges for our investors